Cascade‐Targeted Nanoparticles for Enhanced Gemcitabine Delivery and Adenosine Metabolism Modulation to Overcome Treatment Resistance in Pancreatic Cancer
Advanced Science · 2025
DOI: 10.1002/advs.202507118 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Hongrui Fan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmaceutical Sciences, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of…. Hauptthemen laut MEDLINE: Deoxycytidine, Pancreatic Neoplasms, Adenosine, Nanoparticles. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Science and Technology Major Project, Open Grant from the Pingyuan Laboratory, ZJLab.
Abstract (Originalsprache)
KRAS mutations are find in over 90% of pancreatic ductal adenocarcinoma (PDAC) cases, making PDAC exhibit intrinsic resistance to chemotherapy and reshape the immunosuppressive tumor microenvironment (TME), disappointing the clinically preferred chemotherapy‐immunotherapy combination. Standing on the cross point of therapeutic resistance, the aberrant adenosine metabolism contributes greatly to chemo‐ and immunotherapy tolerance. KRAS mutation‐induced over‐expression of key enzyme CD39 is believed to be involved in shaping the immunosuppressive TME, as it catalyzes the hydrolysis of extracellular ATP into immunosuppressive adenosine. Meanwhile, the loss of equilibrative nucleoside transporters (ENTs) leads to the accumulation of adenosine and the intracellular delivery difficulty of gemcitabine, further vanishing patients’ hope of benefiting from either chemotherapy or immunotherapy. The key challenge is to modulate the aberrant metabolism, also enhance gemcitabine intracellular delivery. Therefore, ROS‐responsive positively‐charged polymer B‐PDEA is prepared and assembled into polyplexes for loading CD39‐down‐regulating small interfering RNA. Gemcitabine‐loaded albumin is coupled with the polyplexes through enzyme‐cleavable peptide, forming the intact nanoparticles for the co‐delivery of the first‐line chemotherapeutic drug and CD39‐regulating nucleic acid, showing enhanced gemcitabine intracellular delivery and adenosine metabolism regulating capacity. This approach activated antitumor immunity while achieving chemosensitization by changing the metabolic‐immune crosstalk of TME, showcasing great potential for PDAC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmaceutical Sciences, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Brain Function and Disorders and MOE Frontiers Center for Brain Scien…
ORCID-Profile: Chen Jiang
Förderung
- Shanghai Municipal Science and Technology Major Project
- Open Grant from the Pingyuan Laboratory
- ZJLab
- Innovative Research Group Project of the National Natural Science Foundation of China
Zitieren
APA
Fan, H., Chen, H., Song, H., Li, C., Wang, Y., Zhao, Z., Guo, Q., Li, X., Liu, M., Sun, T., & Jiang, C. (2025). Cascade‐Targeted Nanoparticles for Enhanced Gemcitabine Delivery and Adenosine Metabolism Modulation to Overcome Treatment Resistance in Pancreatic Cancer. Advanced Science. https://doi.org/10.1002/advs.202507118
Vancouver
Fan H, Chen H, Song H, Li C, Wang Y, Zhao Z, et al. Cascade‐Targeted Nanoparticles for Enhanced Gemcitabine Delivery and Adenosine Metabolism Modulation to Overcome Treatment Resistance in Pancreatic Cancer. Advanced Science. 2025. doi:10.1002/advs.202507118
BibTeX
@article{Fan2025,
author = {Fan, Hongrui and Chen, Hongyi and Song, Haolin and Li, Chufeng and Wang, Yu and Zhao, Zhenhao and Guo, Qin and Li, Xuwen and Liu, Mingxuan and Sun, Tao and Jiang, Chen},
title = {Cascade‐Targeted Nanoparticles for Enhanced Gemcitabine Delivery and Adenosine Metabolism Modulation to Overcome Treatment Resistance in Pancreatic Cancer},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202507118}
}
EUVIMED